secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001171843-26-000174
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR
--------------------------------------------------------------------------------

- Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).
- Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).
- Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.
- 2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.
- 2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/0001171843-26-000174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/f8k_011126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer